[{"id":"be0a0acb-715b-4bf3-8af3-8a6314e2a31f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06514261","created_at":"2025-02-25T20:15:15.595Z","updated_at":"2025-02-25T20:15:15.595Z","phase":"Phase 1","brief_title":"Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML","source_id_and_acronym":"NCT06514261","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • BCL2 • NF1 • MCL1 • BCL2L1 • BAX","pipe":"","alterations":" ","tags":["TP53 • BCL2 • NF1 • MCL1 • BCL2L1 • BAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • iadademstat (ORY-1001)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 12/18/2024","start_date":" 12/18/2024","primary_txt":" Primary completion: 09/16/2026","primary_completion_date":" 09/16/2026","study_txt":" Completion: 09/16/2026","study_completion_date":" 09/16/2026","last_update_posted":"2025-01-16"},{"id":"afaf9f09-288f-48be-befd-287bbb78babe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04734990","created_at":"2021-02-02T15:52:24.117Z","updated_at":"2024-07-02T16:35:04.640Z","phase":"Phase 1/2","brief_title":"Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT04734990","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • NRAS • RUNX1 • ASXL1 • SETBP1","pipe":" | ","alterations":" TP53 mutation • NRAS mutation • ASXL1 mutation","tags":["TP53 • NRAS • RUNX1 • ASXL1 • SETBP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • NRAS mutation • ASXL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • seclidemstat (SP2577)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/07/2021","start_date":" 07/07/2021","primary_txt":" Primary completion: 09/11/2025","primary_completion_date":" 09/11/2025","study_txt":" Completion: 09/11/2025","study_completion_date":" 09/11/2025","last_update_posted":"2024-05-09"},{"id":"370a32d3-7f84-4b34-a0c4-86832be5fec0","acronym":"FRIDA","url":"https://clinicaltrials.gov/study/NCT05546580","created_at":"2022-09-21T21:56:59.855Z","updated_at":"2024-07-02T16:35:18.799Z","phase":"Phase 1","brief_title":"Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)","source_id_and_acronym":"NCT05546580 - FRIDA","lead_sponsor":"Oryzon Genomics S.A.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation • FLT3 D835 • FLT3 I836","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • FLT3 D835 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • iadademstat (ORY-1001)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 07/30/2025","study_completion_date":" 07/30/2025","last_update_posted":"2024-02-19"},{"id":"a010e6ed-344f-428e-a888-60e487dd1787","acronym":"SALA-002-EW16","url":"https://clinicaltrials.gov/study/NCT03600649","created_at":"2021-04-14T16:53:42.104Z","updated_at":"2024-07-02T16:35:28.552Z","phase":"Phase 1","brief_title":"Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas","source_id_and_acronym":"NCT03600649 - SALA-002-EW16","lead_sponsor":"Salarius Pharmaceuticals, LLC","biomarkers":" EWSR1","pipe":"","alterations":" ","tags":["EWSR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • topotecan • seclidemstat (SP2577)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/04/2018","start_date":" 06/04/2018","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-21"},{"id":"58500c01-6437-4480-ae01-c2820de938ce","acronym":"DONIMI","url":"https://clinicaltrials.gov/study/NCT04133948","created_at":"2021-01-18T20:11:28.878Z","updated_at":"2024-07-02T16:35:29.174Z","phase":"Phase 1/2","brief_title":"Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma","source_id_and_acronym":"NCT04133948 - DONIMI","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • domatinostat (4SC-202)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 01/07/2020","start_date":" 01/07/2020","primary_txt":" Primary completion: 01/11/2022","primary_completion_date":" 01/11/2022","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-11-15"},{"id":"266c441e-217f-4fdb-b291-e341689e4674","acronym":"","url":"https://clinicaltrials.gov/study/NCT04628988","created_at":"2021-01-19T20:36:06.920Z","updated_at":"2024-07-02T16:35:37.303Z","phase":"Phase 1","brief_title":"A Study of CC-90011 and Comparators in Participants With Prostate Cancer","source_id_and_acronym":"NCT04628988","lead_sponsor":"Celgene","biomarkers":" AR","pipe":" | ","alterations":" AR expression","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • abiraterone acetate • prednisone • pulrodemstat (CC-90011)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 07/28/2021","start_date":" 07/28/2021","primary_txt":" Primary completion: 05/26/2023","primary_completion_date":" 05/26/2023","study_txt":" Completion: 05/26/2023","study_completion_date":" 05/26/2023","last_update_posted":"2023-09-13"},{"id":"50472ebf-13f3-4a6d-abc3-8b39f9bfd5ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT04611139","created_at":"2021-01-19T20:32:44.176Z","updated_at":"2025-02-25T16:10:47.159Z","phase":"Phase 1","brief_title":"Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers","source_id_and_acronym":"NCT04611139","lead_sponsor":"HonorHealth Research Institute","biomarkers":" ARID1A","pipe":" | ","alterations":" ARID1A mutation","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • seclidemstat (SP2577)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/31/2021","start_date":" 12/31/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2022-03-01"},{"id":"8510abcf-9a1e-4823-bfb7-04eb2abd381d","acronym":"EMERGE","url":"https://clinicaltrials.gov/study/NCT03812796","created_at":"2021-01-18T18:50:37.059Z","updated_at":"2025-02-25T16:08:45.791Z","phase":"Phase 2","brief_title":"Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)","source_id_and_acronym":"NCT03812796 - EMERGE","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • domatinostat (4SC-202)"],"overall_status":"Unknown status","enrollment":" Enrollment 75","initiation":"Initiation: 01/11/2019","start_date":" 01/11/2019","primary_txt":" Primary completion: 11/30/2021","primary_completion_date":" 11/30/2021","study_txt":" Completion: 11/30/2021","study_completion_date":" 11/30/2021","last_update_posted":"2019-02-05"}]